ImmunityBio Shares Surge on Analyst Endorsement and Expanded Market Access

ImmunityBio shares surged 11% on a BTIG Buy rating and a key NCCN guideline inclusion for its cancer drug ANKTIVA, which saw 700% sales growth.

A potent combination of bullish analyst coverage and significant regulatory progress provided a substantial boost to ImmunityBio’s stock at the beginning of the trading week. The biotechnology firm’s shares experienced a notable uptick, driven by accelerating commercial performance for its cancer therapy and new clinical guidelines that broaden its potential patient base.

Analyst Initiates Coverage with Strong Conviction

The immediate catalyst for Monday’s rally, which saw the stock advance by approximately eleven percent at its peak, was a new research report from investment bank BTIG. Analysts at the firm initiated coverage on ImmunityBio with a “Buy” rating, assigning a price target of $13 per share. This target represents a significant premium to the current trading level and is predicated on expectations for rising revenue and upcoming regulatory milestones.

Updated Guidelines and Global Expansion Fuel Growth Narrative

Beyond the analyst endorsement, a key development supporting the optimistic outlook is a recent update to the National Comprehensive Cancer Network (NCCN) guidelines. The 2026 version now includes a recommendation for ImmunityBio’s drug, ANKTIVA, for patients with purely papillary, non-muscle invasive bladder cancer. This classification is particularly noteworthy as it extends beyond the therapy’s current FDA-approved label. Such guidelines frequently influence physician prescribing habits and insurance reimbursement decisions even prior to formal regulatory approval for the expanded indication.

Should investors sell immediately? Or is it worth buying ImmunityBio?

This medical validation is complemented by advances in the company’s international strategy. ANKTIVA recently secured its first approval in Asia, granted by authorities in Macau who referenced its existing clearances in the United States and Europe. The therapy is now available in 34 countries and territories worldwide.

Financial Performance Shows Rapid Commercial Traction

The company’s financial results underscore its commercial momentum. For fiscal year 2025, ImmunityBio reported net sales of approximately $113 million for ANKTIVA. This figure marks a dramatic year-over-year increase of 700 percent, driven by substantially higher sales volume. This robust growth, however, coincides with a net loss of $61.9 million for the most recent quarter. Management’s current strategy prioritizes rapid market penetration and clinical development over achieving short-term profitability.

With cash reserves of around $250 million, the company is funded for its near-term expansion plans. The next concrete milestone is already in view: in March 2026, ImmunityBio resubmitted its supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the papillary disease indication. The agency’s decision on this application is expected to be a major determinant of the company’s future commercial opportunity in the U.S. market.

ImmunityBio Stock: New Analysis – 24 March

Fresh ImmunityBio information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis…